The three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC phase 3 clinical trial.
Prof. Scott Kopetz (MD Anderson Cancer Center, Houston, USA) presented the international collaboration, which included >200 centres worldwide in this open label, three-arm randomised clinical trial. A total of 665 patients with BRAF V600E-mutant mCRC who had progressed after one or two prior regimens in the metastatic setting were randomised to receive triplet therapy, doublet therapy (encorafenib and cetuximab), or the investigator’s choice of irinotecan or folinic acid, fluoruracil and irinotecan (FOLFIRI) and cetuximab . BRAF mutations are estimated to occur in up to 15% of patients with mCRC, with V600E being the most ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Nivolumab+ipilimumab superior to monotherapy for melanoma brain metastases Next Article
Novel mode of action for kidney cancer treatment »
Table of Contents: ESMO 2019
Solid tumours/pan-tumour data
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.